BLA 125460 · Biomarin Pharm
Vimizim
Elosulfase Alfa · Injection · Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Oct 30, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Feb 14, 2014
Approved uses
1
Original approval plus efficacy supplements
Registered trials
5
2 Phase 3, 1 recruiting
FAERS reports
5,517
2,246 serious, 134 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS and RISK OF ACUTE RESPIRATORY COMPLICATIONS Patients treated with enzyme replacement therapies have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy. Initiate VIMIZIM in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue VIMIZIM and immediately initiate appropriate medical treatment, including use of epinephrine. Inform patients of the symptoms of life-threatening hypersensitivity reactions, including anaphylaxis and to seek immediate medical care should symptoms occur [see Warnings and Precautions (5.1) ] . Patients...
What it is approved for
From the label in effect Oct 30, 2025.
VIMIZIM (elosulfase alfa) is indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome). VIMIZIM is a hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome). ( 1 )
Mechanism: Mucopolysaccharidoses comprise a group of lysosomal storage disorders caused by the deficiency of specific lysosomal enzymes required for the catabolism of glycosaminoglycans (GAG). Mucopolysaccharidosis IVA (MPS IVA, Morquio A Syndrome) is characterized by the absence or marked reduction in N -acetylgalactosamine-6-sulfatase activity. The sulfatase activity deficiency results in the accumulation of the GAG substrates, KS and C6S, in the lysosomal compartment of cells throughout the body. The accumulation leads to widespread cellular, tissue, and organ dysfunction. VIMIZIM is intended to...
Therapeutic areas: Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 14, 2014 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelSummary ReviewLetter
1 products under this application
- VIMIZIM · ELOSULFASE ALFA 5MG/5ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Elosulfase Alfa" as an intervention, any sponsor and status, largest first.
- A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)Pivotal-lookingCompleted
BioMarin PharmaceuticalBioMarin (BMRN)
NCT01275066 · 177 participants · Start Feb 2011 · Primary completion Aug 2012
Drug: BMN 110 Weekly; Placebo and 1 more · For: MPS IV A
Sites: Oakland, California; Wilmington, Delaware; Washington D.C., District of Columbia · 28 sites in all
BioMarin PharmaceuticalBioMarin (BMRN)
NCT01609062 · 25 participants · Start Apr 2012 · Primary completion Nov 2014
Drug: BMN 110; BMN 110 · For: Mucopolysaccharidosis IVA; Morquio A Syndrome; MPS IVA
Sites: Oakland, California; Chicago, Illinois; New York, New York · 11 sites in all
- Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited AmbulationTerminated
BioMarin PharmaceuticalBioMarin (BMRN)
NCT01697319 · 16 participants · Start Aug 2012 · Primary completion Oct 2014
Drug: BMN 110 · For: Mucopolysaccharidosis IVA; Morquio A Syndrome; MPS IVA
Sites: Oakland, California; Chicago, Illinois; Hamburg, Germany · 7 sites in all
- BMN 110 Phase 3B in Australian PatientsPivotal-lookingCompleted
BioMarin PharmaceuticalBioMarin (BMRN)
NCT01966029 · 13 participants · Start Jul 2013 · Primary completion Jul 2016
Drug: BMN 110 · For: Mucopolysaccharidosis IVA (Morquio A Syndrome)
Sites: Westmead, Australia; Brisbane, Australia; Melbourne, Australia · 5 sites in all
University of California, San FranciscoAcademic, hospital or other
NCT04532047 · 10 participants (planned) · Start Jul 1, 2021 · Primary completion Jul 31, 2031
Drug: Aldurazyme (laronidase) · For: MPS I; MPS II; MPS IVA and 6 more
Sites: San Francisco, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pyrexia742
- cough353
- vomiting333
- malaise287
- headache261
- pain241
- dyspnoea238
- nausea228
- fatigue202
- nasopharyngitis199
- pneumonia172
- oxygen saturation decreased155
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2014 | 151 |
| 2015 | 436 |
| 2016 | 526 |
| 2017 | 445 |
| 2018 | 440 |
| 2019 | 470 |
| 2020 | 406 |
| 2021 | 475 |
| 2022 | 465 |
| 2023 | 467 |
| 2024 | 425 |
| 2025 | 460 |
| 2026 | 351 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Vimizim (Elosulfase Alfa)
2024 spending
$15.5M
Beneficiaries
16
156 claims
Per beneficiary
$965,713
$286.19 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $13,459,121 |
| 2021 | $13,731,158 |
| 2022 | $13,803,740 |
| 2023 | $16,893,194 |
| 2024 | $15,451,405 |
Part B: Vimizim (Elosulfase Alfa) · HCPCS J1322
2024 spending
$2.6M
Beneficiaries
n/a
110 claims
Per beneficiary
n/a
2024 ASP limit $286.65 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,415,712 |
| 2021 | $2,197,743 |
| 2022 | $2,027,234 |
| 2023 | $2,169,684 |
| 2024 | $2,569,194 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy of different treatment strategies in patients with mucopolysaccharidosis: a systematic review and network meta-analysis of randomized controlled trials.
Huang L, Wu J, Tang B, et al. · Orphanet J Rare Dis 2025 · Network Meta-Analysis, Systematic Review
- Impact of long-term elosulfase alfa treatment on respiratory function in patients with Morquio A syndrome.
Hendriksz CJ, Berger KI, Parini R, et al. · J Inherit Metab Dis 2016 · Clinical Trial, Phase III, Multicenter Study
- Clinical outcomes in a subpopulation of adults with Morquio A syndrome: results from a long-term extension study of elosulfase alfa.
Hughes D, Giugliani R, Guffon N, et al. · Orphanet J Rare Dis 2017 · Clinical Trial, Phase III, Multicenter Study
- Safety and clinical activity of elosulfase alfa in pediatric patients with Morquio A syndrome (mucopolysaccharidosis IVA) less than 5 y.
Jones SA, Bialer M, Parini R, et al. · Pediatr Res 2015 · Clinical Trial, Phase II, Multicenter Study
- Long-term endurance and safety of elosulfase alfa enzyme replacement therapy in patients with Morquio A syndrome.
Hendriksz CJ, Parini R, AlSayed MD, et al. · Mol Genet Metab 2016 · Clinical Trial, Phase III, Multicenter Study
- Antibodies that neutralize cellular uptake of elosulfase alfa are not associated with reduced efficacy or pharmacodynamic effect in individuals with Morquio A syndrome.
Melton AC, Soon RK, Tompkins T, et al. · J Immunol Methods 2017 · Clinical Trial, Phase III, Multicenter Study
Sponsor: BioMarin
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.